Vetter Continues to Strengthen its Market Position
News Jan 15, 2014
Vetter has announced that 2013 was yet another growth year for the company. As evidenced by a growing demand for customer projects in clinical phases and commercial aseptic manufacturing, the CDMO increased sales by more than 10 percent.
Currently the company employs around 3,300 people at its German and US facilities. This sustained, positive development by the company was made possible as a result of its high quality and safety standards, as well as investments made across the company’s facilities for process optimization.
With an increase in market demand, Vetter responded by strengthening and reinforcing its position as a strategic partner for both the development phase, and commercial manufacturing of parenteral drugs.
These actions included the increase in its capacities and service portfolio in production sites in Germany and the US. The company is planning the implementation of three new filling lines and is also making investments in innovative technologies.
Vetter will also continue to optimize its quality management and processes in manufacturing and logistics to support pharmaceutical and biotech companies in meeting market requirements of quality and safety.
Still another reason for the strong growth is the newly launched customer projects at Vetter’s Chicago site. Here the company supports its customers in process development and manufacturing of clinical trials during product development.
Once the clinical development phases are completed, the product it transferred to the German facilities for commercial production and market supply.
"Increasingly, our customers rely on our expertise and more than thirty-five years of experience in aseptic filling of injection systems," said Vetter Managing Director Peter Soelkner. “Next to a reliable production for continuous market supply, we also supported our customers with their complex development projects with our Development Service both in Chicago and Ravensburg."
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018